---
title: "Augmented Trials Mixing Randomized and Observational Data for Postnatal HIV Prophylaxis"
id: "medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1?rss=1"
published_at: "2026-10-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Augmented Trials Mixing Randomized and Observational Data for Postnatal HIV Prophylaxis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1?rss=1)
- **Published At:** 2026-10-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators propose an **augmented clinical trial design** that integrates a concurrent observational cohort with a randomized trial featuring an active comparator to study infant **postnatal prophylaxis** against **HIV**. - The design aims to address infeasibility of large **randomized controlled trials** given the high efficacy of existing antiretroviral interventions, which reduce event rates and thus inflate required sample sizes. - In the proposed approach, the randomized component includes an active comparator arm; a simultaneously enrolled observational cohort supplements that comparator arm, increasing effective sample size without enlarging the randomized allocation proportion. - Authors reported an illustrative trial using a 3:1 allocation in the randomized component; the augmented analysis produced an unbiased treatment effect estimate relative to the randomized trial alone and materially reduced the standard error. - The source described that the augmented trial’s total sample size exceeded that of a similarly powered 1:1 standard trial, but the randomized trial component was about half the size of the standard trial — a practical advantage for recruitment and historically comparable trial sizes. - A diagnostic procedure to evaluate potential bias from unmeasured covariates accompanies the analytic strategy; the manuscript noted this diagnostic can identify when unmeasured confounding may threaten validity. - The study team examined performance through simulation; simulations evaluated bias mitigation and precision gains but the source did not specify all simulation parameters in the abstract. - Authors acknowledged limitations inherent to combining observational data with randomized data and advised rigorous planning and coordination to mitigate these concerns; they provided code on GitHub for transparency. - The work was presented as a methodological solution applicable to assessing **long-acting antiretrovirals** for infant prophylaxis, with competing interests disclosed for one author and data/code availability noted.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Combining Randomized and Observational Data: The Case of Postnatal Prophylaxis Against HIV [ View ORCID Profile](http://orcid.org/0000-0002-8599-1004)Dwight Edward Yin, [ View ORCID Profile](http://orcid.org/0000-0002-9932-1095)Paul N Zivich, [ View ORCID Profile](http://orcid.org/0000-0003-2255-9756)Mark J Giganti, [ View ORCID Profile](http://orcid.org/0000-0002-6989-735X)Danni Wu, [ View ORCID Profile](http://orcid.org/0000-0002-1741-335X)Jessie K Edwards, Stephen R Cole doi: https://doi.org/10.64898/2026.10.15.26365628 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Dwight Edward Yin 1 Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dwight%2BEdward%2BYin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yin%20DE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADwight%2BEdward%2BYin%2B) * [ORCID record for Dwight Edward Yin](http://orcid.org/0000-0002-8599-1004 "Open in new tab") * For correspondence: dwight.yin@nih.gov Paul N Zivich 2 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paul%2BN%2BZivich%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zivich%20PN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaul%2BN%2BZivich%2B) * [ORCID record for Paul N Zivich](http://orcid.org/0000-0002-9932-1095 "Open in new tab") Mark J Giganti 3 Center for Biostatistics and AIDS Research, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mark%2BJ%2BGiganti%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Giganti%20MJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMark%2BJ%2BGiganti%2B) * [ORCID record for Mark J Giganti](http://orcid.org/0000-0003-2255-9756 "Open in new tab") Danni Wu 3 Center for Biostatistics and AIDS Research, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Danni%2BWu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wu%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADanni%2BWu%2B) * [ORCID record for Danni Wu](http://orcid.org/0000-0002-6989-735X "Open in new tab") Jessie K Edwards 2 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessie%2BK%2BEdwards%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Edwards%20JK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJessie%2BK%2BEdwards%2B) * [ORCID record for Jessie K Edwards](http://orcid.org/0000-0002-1741-335X "Open in new tab") Stephen R Cole 2 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stephen%2BR%2BCole%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cole%20SR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStephen%2BR%2BCole%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1323734/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1323734/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1323734/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1323734/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1323734/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract The efficacy of current antiretroviral interventions for prevention of vertical HIV transmission is both a triumph and a challenge for future efficacy studies of novel agents, including long-acting antiretroviral agents. Given the effectiveness of current antiretroviral interventions, standard randomized controlled trials to assess novel interventions targeted towards further reducing vertical HIV transmission may be infeasible due to required sample sizes. To address this study design challenge, we propose a novel augmented clinical trial design, where a randomized trial with an active comparator is augmented with a concurrent observational cohort to supplement the standard-of-care arm. The proposed design and analysis can overcome sampling biases, and an associated diagnostic can evaluate potential biases from unmeasured covariates. The proposed trial design is illustrated with an example and studied further using a simulation study. In the illustrative example, an augmented trial with a 3:1 allocation ratio in the trial component yielded an unbiased treatment effect estimate, as compared to the trial component alone, and the standard error was reduced substantially. Although the total sample size of the augmented trial was larger than a similarly powered 1:1 standard trial, the sample size of the augmented trial's trial component was half the size of the standard trial and within the range of historically similar trials, thereby providing both feasibility and potential cost advantages. Although limitations with this design remain, many of these limitations can be mitigated by careful study planning and coordination. Augmented trials provide a potentially applicable solution to studying the efficacy of long-acting antiretrovirals for infant postnatal prophylaxis against HIV. ### Competing Interest Statement MJG has received research support from ViiV Healthcare paid to his institution. The remaining authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Code is available at https://github.com/pzivich/publications-code. ## Funder Information Declared National Institute of Allergy and Infectious Diseases, P30AI50410, R01AI157758, K01AI177102, UM1AI068616-15 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.14.26365591v1 "Does the Disease-free Survival Benefit of Adding Belzutifan to Adjuvant Pembrolizumab Persist Beyond the Planned Treatment Period? A Reconstructed Individual Patient Data Analysis of Phase 3 Renal Cell Carcinoma Trials")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.23.26363766v2 "A prospective case-control study of the gut bacteriome and mycobiome in glioblastoma") Posted October 16, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/16/2026.10.15.26365628.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.15.26365628v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/16/2026.10.15.26365628.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Combining Randomized and Observational Data: The Case of Postnatal Prophylaxis Against HIV Dwight Edward Yin, Paul N Zivich, Mark J Giganti, Danni Wu, Jessie K Edwards, Stephen R Cole medRxiv 2026.10.15.26365628; doi: https://doi.org/10.64898/2026.10.15.26365628 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.15.26365628v1%26text%3DCombining%2520Randomized%2520and%2520Observational%2520Data%253A%2520The%2520Case%2520of%2520Postnatal%2520Prophylaxis%2520Against%2520HIV "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.15.26365628v1%26t%3DCombining%2520Randomized%2520and%2520Observational%2520Data%253A%2520The%2520Case%2520of%2520Postnatal%2520Prophylaxis%2520Against%2520HIV "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.15.26365628v1%26title%3DCombining%2520Randomized%2520and%2520Observational%2520Data%253A%2520The%2520Case%2520of%2520Postnatal%2520Prophylaxis%2520Against%2520HIV%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.15.26365628v1%26title%3DCombining%2520Randomized%2520and%2520Observational%2520Data%253A%2520The%2520Case%2520of%2520Postnatal%2520Prophylaxis%2520Against%2520HIV "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.15.26365628) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.15.26365628v1&count=horizontal&via=&text=Combining%20Randomized%20and%20Observational%20Data%3A%20The%20Case%20of%20Postnatal%20Prophylaxis%20Against%20HIV&counturl=www.medrxiv.org/content/10.64898/2026.10.15.26365628v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (629) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (343) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4927) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (488) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (422) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (667) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1659) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16132) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (35) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1229) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7176) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (741) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1081) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5190) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1453) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1811) * [Hematology](https://www.medrxiv.org/collection/hematology) (596) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1366) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16404) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1189) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (687) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (734) * [Neurology](https://www.medrxiv.org/collection/neurology) (7451) * [Nursing](https://www.medrxiv.org/collection/nursing) (374) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1111) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1275) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1024) * [Oncology](https://www.medrxiv.org/collection/oncology) (3694) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1077) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (400) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (461) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (488) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (142) * [Pathology](https://www.medrxiv.org/collection/pathology) (715) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1838) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (745) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (780) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6043) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9890) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2482) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1495) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1260) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (655) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (792) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (591) * [Surgery](https://www.medrxiv.org/collection/surgery) (794) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (314) * [Urology](https://www.medrxiv.org/collection/urology) (300) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been tran
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Beyond conventional biomarkers: editorial on novel biomarkers and combinatorial approaches for imm](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-editorial-beyond-conventional-biomarkers-unlocking-immunotherapy-response.md)
- [mRNA vaccines vindicated: mFlusiva approval and subsequent data after HHS cancellations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-one-year-since-kennedy-canceled-mrna-vaccine-projects-science-shows-how.md)
- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.